On June 16 local time, neuroscience company 4E Therapeutics, Inc. announced that it has been acquired by Eli Lilly and Company.
4E is dedicated to developing next-generation non-opioid therapies for chronic pain and is currently advancing a pipeline of oral MNK inhibitors designed to treat chronic pain by targeting the MNK-eIF4E signaling pathway in peripheral sensory neurons. These compounds are designed to provide significant pain relief while avoiding the central nervous system effects associated with many existing therapies.
4ET1103 is the company’s first MNK inhibitor to enter human clinical trials for the treatment of pain, and has demonstrated a favorable safety profile in Phase 1 studies.
Buy 4ET1103 from China and save up to 80% on costs . no insurance needed . compare prices from a certified HongKong pharmacy .with fast shipping. Contact us now on WhatsApp to get the latest prices.
